The biopharmaceutical sector is active, and Wise Medicine hits the daily limit.

MaticHoleFiller · 2026-04-02T11:35:59+00:00

April 1 News, as of 13:35, the biotechnology and pharmaceutical sector is active, with RuiZhi Pharmaceuticals, LianHuan Pharmaceuticals, and Kingmed Biological hitting the daily limit. ChengDa Pharmaceuticals, BaiPuSais, ZhiFei Biological, BoTeng Co., Ltd., FuXiang Pharmaceuticals, KangChen Pharmaceuticals, LingKang Pharmaceuticals (rights protection), and other stocks are among the top gainers.Disclaimer: The market carries risks; please invest cautiously. This article is automatically published based on third-party databases and does not represent Sina Finance's views. Any information appearing in this article is for reference only and does not constitute personal investment advice. Please refer to official announcements for the actual situation. If you have any questions, contact biz@staff.sina.com.cn.

MaticHoleFiller

2026-04-02 11:35:59

April 01 news: As of 13:35, the biopharmaceutical sector is active. Ruisong Biopharmaceutical, Lianhuan Pharmaceutical, and Haiwang Bio are all up to the limit. Chengda Pharmaceutical, Biobest, Zhifei Bio, Boteng Co., Ltd., Fuxiang Pharmaceutical, Kangchen Pharmaceutical, and Lingkang Pharmaceutical (rights protection) are among the leading gainers.

Statement: The market involves risks; investment requires caution. This article is automatically published based on third-party databases and does not represent the views of Sina Finance. Any information appearing in this article is for reference only and does not constitute personal investment advice. If there are any discrepancies, please refer to the actual announcements. If you have any questions, please contact biz@staff.sina.com.cn.

A wealth of information and precise insights—inside the Sina Finance app

Responsible editor: Xiaolang Kuaibao

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.